243 related articles for article (PubMed ID: 33497479)
41. Metastatic Colorectal Cancer Treatment Response Evaluation by Ultra-Deep Sequencing of Cell-Free DNA and Matched White Blood Cells.
van 't Erve I; Medina JE; Leal A; Papp E; Phallen J; Adleff V; Chiao EJ; Arun AS; Bolhuis K; Simmons JK; Karandikar A; Valkenburg KC; Sausen M; Angiuoli SV; Scharpf RB; Punt CJA; Meijer GA; Velculescu VE; Fijneman RJA
Clin Cancer Res; 2023 Mar; 29(5):899-909. PubMed ID: 36534496
[TBL] [Abstract][Full Text] [Related]
42. Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas.
Hickmann AK; Frick M; Hadaschik D; Battke F; Bittl M; Ganslandt O; Biskup S; Döcker D
BMC Cancer; 2019 Mar; 19(1):192. PubMed ID: 30823914
[TBL] [Abstract][Full Text] [Related]
43. Clonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications.
Chan HT; Chin YM; Nakamura Y; Low SK
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32823942
[TBL] [Abstract][Full Text] [Related]
44. Molecular genetic profiling reveals novel association between FLT3 mutation and survival in glioma.
Shee K; Chambers M; Hughes EG; Almiron DA; Deharvengt SJ; Green D; Lefferts JA; Andrew AS; Hickey WF; Tsongalis GJ
J Neurooncol; 2020 Jul; 148(3):473-480. PubMed ID: 32583303
[TBL] [Abstract][Full Text] [Related]
45. Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study.
Bagley SJ; Nabavizadeh SA; Mays JJ; Till JE; Ware JB; Levy S; Sarchiapone W; Hussain J; Prior T; Guiry S; Christensen T; Yee SS; Nasrallah MP; Morrissette JJD; Binder ZA; O'Rourke DM; Cucchiara AJ; Brem S; Desai AS; Carpenter EL
Clin Cancer Res; 2020 Jan; 26(2):397-407. PubMed ID: 31666247
[TBL] [Abstract][Full Text] [Related]
46. Combinatory Analysis of Cell-free and Circulating Tumor Cell DNAs Provides More Variants for Cancer Treatment.
Lee SY; Chae DK; An J; Yoo S; Jung S; Chae CH; Bhak J; Kim BC; Cho DH
Anticancer Res; 2019 Dec; 39(12):6595-6602. PubMed ID: 31810925
[TBL] [Abstract][Full Text] [Related]
47. Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients.
Palande V; Raviv Shay D; Frenkel-Morgenstern M
J Vis Exp; 2020 Sep; (163):. PubMed ID: 32986022
[TBL] [Abstract][Full Text] [Related]
48. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
[TBL] [Abstract][Full Text] [Related]
49. Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.
Qiu X; Chen Y; Bao Z; Chen L; Jiang T
Radiother Oncol; 2022 Feb; 167():1-6. PubMed ID: 34902368
[TBL] [Abstract][Full Text] [Related]
50. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.
Razavi P; Li BT; Brown DN; Jung B; Hubbell E; Shen R; Abida W; Juluru K; De Bruijn I; Hou C; Venn O; Lim R; Anand A; Maddala T; Gnerre S; Vijaya Satya R; Liu Q; Shen L; Eattock N; Yue J; Blocker AW; Lee M; Sehnert A; Xu H; Hall MP; Santiago-Zayas A; Novotny WF; Isbell JM; Rusch VW; Plitas G; Heerdt AS; Ladanyi M; Hyman DM; Jones DR; Morrow M; Riely GJ; Scher HI; Rudin CM; Robson ME; Diaz LA; Solit DB; Aravanis AM; Reis-Filho JS
Nat Med; 2019 Dec; 25(12):1928-1937. PubMed ID: 31768066
[TBL] [Abstract][Full Text] [Related]
51. Cell-Free DNA Variables including Gene Mutations in CA15-3 Normal Breast Cancer Reflect Prognosis.
Xu J; Chen W; Sun Z; Peng H; Zhou C; Pan S
Dis Markers; 2022; 2022():5470166. PubMed ID: 35251373
[TBL] [Abstract][Full Text] [Related]
52. Sputum cell-free DNA for detection of alterations of multiple driver genes in lung adenocarcinoma.
Wang Z; Li L; Wang Y; Li X; Xu Y; Wang M; Liang L; Wu X; Tang M; Li Y; He S; Du J; He L; Sun M; Yang L; Di J; Gai F; Liu D
Cancer Cytopathol; 2023 Feb; 131(2):110-116. PubMed ID: 36103360
[TBL] [Abstract][Full Text] [Related]
53. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer.
Chin YM; Takahashi Y; Chan HT; Otaki M; Fujishima M; Shibayama T; Miki Y; Ueno T; Nakamura Y; Low SK
Cancer Sci; 2021 Jan; 112(1):454-464. PubMed ID: 33075187
[TBL] [Abstract][Full Text] [Related]
54. Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients.
Wang Q; He Z; Chen Y
Cancer Control; 2019; 26(1):1073274819855118. PubMed ID: 31167546
[TBL] [Abstract][Full Text] [Related]
55. Identification of Potential Genomic Alterations Using Pan-Cancer Cell-Free DNA Next-Generation Sequencing in Patients With Gastric Cancer.
Kim B; Kim Y; Cho JY; Lee KA
Ann Lab Med; 2024 Mar; 44(2):164-173. PubMed ID: 37903652
[TBL] [Abstract][Full Text] [Related]
56. Feasibility Analysis of Cell-Free DNA Derived from Plasma of Lung Cancer Patients for Next-Generation Sequencing.
Jiang X; Li H; Liu J; Sun H; Zhang L; Li W; Yao J; Cheng Y
Biopreserv Biobank; 2020 Apr; 18(2):117-121. PubMed ID: 32083487
[No Abstract] [Full Text] [Related]
57. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
[TBL] [Abstract][Full Text] [Related]
58. Genomewide copy number alteration screening of circulating plasma DNA: potential for the detection of incipient tumors.
Lenaerts L; Vandenberghe P; Brison N; Che H; Neofytou M; Verheecke M; Leemans L; Maggen C; Dewaele B; Dehaspe L; Vanderschueren S; Dierickx D; Vandecaveye V; Amant F; Vermeesch JR
Ann Oncol; 2019 Jan; 30(1):85-95. PubMed ID: 30371735
[TBL] [Abstract][Full Text] [Related]
59. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.
Möhrmann L; Huang HJ; Hong DS; Tsimberidou AM; Fu S; Piha-Paul SA; Subbiah V; Karp DD; Naing A; Krug A; Enderle D; Priewasser T; Noerholm M; Eitan E; Coticchia C; Stoll G; Jordan LM; Eng C; Kopetz ES; Skog J; Meric-Bernstam F; Janku F
Clin Cancer Res; 2018 Jan; 24(1):181-188. PubMed ID: 29051321
[No Abstract] [Full Text] [Related]
60. GNAS mutation detection in circulating cell-free DNA is a specific predictor for intraductal papillary mucinous neoplasms of the pancreas, especially for intestinal subtype.
Hata T; Mizuma M; Motoi F; Omori Y; Ishida M; Nakagawa K; Hayashi H; Morikawa T; Kamei T; Furukawa T; Unno M
Sci Rep; 2020 Oct; 10(1):17761. PubMed ID: 33082481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
